This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
3-MeO-PCP: Difference between revisions
>Unity Content overhaul. |
>Unity m Grammatics |
||
| Line 5: | Line 5: | ||
'''3-Methoxyphencyclidine''' (also known as '''3-MeO-PCP''') is a lesser-known novel [[Psychoactive class::dissociative]] substance of the [[Chemical class::arylcyclohexylamine]] class. 3-MeO-PCP is a derivative of [[phencyclidine]] ('''PCP''') and is chemically related to compounds like [[methoxetamine]] and [[3-MeO-PCE]]. It produces its effects by blocking the activity of [[NMDA receptor|NMDA receptors]] in the brain. | '''3-Methoxyphencyclidine''' (also known as '''3-MeO-PCP''') is a lesser-known novel [[Psychoactive class::dissociative]] substance of the [[Chemical class::arylcyclohexylamine]] class. 3-MeO-PCP is a derivative of [[phencyclidine]] ('''PCP''') and is chemically related to compounds like [[methoxetamine]] and [[3-MeO-PCE]]. It produces its effects by blocking the activity of [[NMDA receptor|NMDA receptors]] in the brain. | ||
3-MeO-PCP was first synthesized in 1979 in an investigation of [[phencyclidine]] (PCP) derivatives. However, its activity in humans was not described until 1999 when a chemist using the pseudonym John Q. Beagle reported qualitative similarities to [[PCP]] along with comparable potency.<ref name="PCP2MXE">Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis, 6(7–8), 614–632. https://doi.org/10.1002/dta.1620</ref> In 2009, it began to be discussed on online forums such as bluelight.ru and made available for sale on the [[research chemicals]] market.<ref>Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis, 6(7–8), 614–632. https://doi.org/10.1002/dta.1620</ref> | 3-MeO-PCP was first synthesized in 1979 in an investigation of [[phencyclidine]] (PCP) derivatives. However, its activity in humans was not described until 1999 when a chemist using the pseudonym John Q. Beagle reported qualitative similarities to [[PCP]] along with comparable potency.<ref name="PCP2MXE">Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis, 6(7–8), 614–632. https://doi.org/10.1002/dta.1620</ref> In 2009, it began to be discussed on online forums such as bluelight.ru and was made available for sale on the [[research chemicals]] market.<ref>Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis, 6(7–8), 614–632. https://doi.org/10.1002/dta.1620</ref> | ||
Like other arylcyclohexlyamines, 3-MeO-PCP induces a state referred to as "[[dissociatives#Subjective effects|dissociative anesthesia]]", although the extent to which this occurs is reported to be highly dose-dependent and variable in its effects. It is commonly taken [[orally]] and [[nasally]], although it may also be [[smoked]] and [[injected]]. It has been noted for its subtle come up and tendency to produce [[Delusions#Delusion of sobriety|delusions of sobriety]], which can lead to [[compulsive redosing]]. | Like other arylcyclohexlyamines, 3-MeO-PCP induces a state referred to as "[[dissociatives#Subjective effects|dissociative anesthesia]]", although the extent to which this occurs is reported to be highly dose-dependent and variable in its effects. It is commonly taken [[orally]] and [[nasally]], although it may also be [[smoked]] and [[injected]]. It has been noted for its subtle come up and tendency to produce [[Delusions#Delusion of sobriety|delusions of sobriety]], which can lead to [[compulsive redosing]]. | ||